Title:
COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/185468
Kind Code:
A9
Abstract:
The present invention belongs to the field of synthesis of heterocyclic compound drugs with a nitrogen atom as a heterocyclic atom; particularly relates to a compound used as a kinase inhibitor and the use thereof; and also relates to the preparation of a free base crystal form of the compound. The compound used as a kinase inhibitor is a compound as shown in formula 1, or a deuterated compound thereof, or a pharmaceutically acceptable salt, solvate or prodrug. Biological activity experiments prove that the above compound has a good inhibitory activity on exon 20 insertion mutations in EGFR and Her2, exon 19 deletion in EGFR and exon 21 point mutation in EGFR, and can be used as the bulk drug in relevant drugs.
Inventors:
LI JUN (CN)
WU YUSHENG (CN)
NIU CHENGSHAN (CN)
GUO ZHONGWEI (CN)
LIANG APENG (CN)
WU YUSHENG (CN)
NIU CHENGSHAN (CN)
GUO ZHONGWEI (CN)
LIANG APENG (CN)
Application Number:
PCT/CN2023/081557
Publication Date:
November 02, 2023
Filing Date:
March 15, 2023
Export Citation:
Assignee:
TYK MEDICINES INC (CN)
TYK MEDICINES ZHENGZHOU INC (CN)
TYK MEDICINES ZHENGZHOU INC (CN)
International Classes:
C07D403/14; A61P35/00; C07D401/14; C07D413/14
Attorney, Agent or Firm:
ZHENGZHOU RUIXIN INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: